Pharmaceuticals

As DuPont prepares to reveal a new Tyvek® for ASEAN, the focus shifts from mere compliance to integrating comfort, productivity, and holistic worker safety.

Faculty's new AI developer studio promises to cut drug trial planning from weeks to minutes, a major growth signal in the high-stakes life sciences race.

Enterprises are stuck between rapid AI prototyping and the slow, necessary grind of governance. Dataiku's new AI agent, Cobuild, promises to unite them.

A Chinese firm is expanding its role in the hidden, high-stakes supply chain for semiconductors and advanced manufacturing. Here’s why it matters.

Icelandic biotech Alvotech seeks $125M in a complex dual offering to advance its low-cost drug pipeline, but regulatory hurdles and financial pressures loom.

Verastem Oncology is preparing to show its hand with VS-7375, a novel dual-action KRAS G12D inhibitor. Can its unique science disrupt a crowded market?

HPE's new quantum strategy isn't just about qubits; it's about building a resilient bridge between classical HPC and the quantum future.

AIRA ushers in new leadership with Boris Steffen as President, poised to navigate economic turbulence and shape the future of the insolvency profession.

The FDA's approval of a new Type 1 Diabetes therapy is a landmark. But the real story is the collaborative engine clearing the path for future breakthroughs.

In the chaotic, high-stakes world of pharma tradeshows, success is no longer about free pens. It's about strategy, psychology, and navigating regulations.

Nordicus Partners reveals promising data for gum disease and oral lesions, betting its future on a unique Nordic acquisition strategy and a Nasdaq uplisting.

A new clinical trial, backed by the Michael J. Fox Foundation, tests a radical idea: an oral drug derived from carbon monoxide to fight Parkinson's.

A new strategic partnership aims to overcome drug resistance in GI cancers by combining Lonza's advanced ADC platform with Antharis's targeted antibody expertise.

New Phase 3 data for Takeda's oveporexton shows it treats the root cause of narcolepsy, not just symptoms. A key FDA decision looms this year.

Tri Delta’s 27-year, $185M partnership with St. Jude is more than charity. It's a masterclass in grassroots economic power fueling life-saving innovation.

As AI promises to revolutionize medicine, enterprises face complex challenges. A new ISG study aims to chart the critical partner ecosystem.

As AI drug discovery faces a crucial test, Terray Therapeutics hires a proven dealmaker. Can Lisa Decker translate digital promise into clinical reality?

Big Pharma is pouring over $1 billion into AI to design complex drugs, trading lab guesswork for algorithms. It's a high-stakes play to fix a broken R&D model.

New clinical trial results for XWRAP® show a significant leap in healing diabetic ulcers, positioning Applied Biologics as a formidable player in a challenging field.

With air quality plummeting, a new wellness market is booming. We investigate the science and business behind lung health supplements for wildfire season.